Dear Shareholders and Investors:
It is very fortunate that on December 10, 2018, the Korea Exchange decided to resume the stock trading of Samsung Biologics (the “Company”) in order to protect investors.
With the KOSPI listing in 2016, the Company changed its management practice from management centered on inside directors to management centered on independent directors, thereby improving its management transparency.
Also, since August 2016, the Company has further improved its management transparency by establishing and operating an audit committee whose chairman is an accounting professor.
The Company, as a global biotechnology company, plans to further strengthen its management transparency in order to better meet the market and social needs as follows:
1. Strengthen the internal control system for prevention and post-verification (2nd quarter of 2019)
- After reviewing current business process, build and operate an efficient and powerful internal control system based thereon
2. Enhance the practical auditing function by improving items that are insufficient than as directed
in the Audit Committee's Model Guidelines (1st quarter of 2019)
- Promote periodic inspection and strengthen the support system with an external professional agency
3. Specialize supervision function of the internal accounting management through the operation of
the Audit Committee (1st quarter of 2019)
- Strengthen the support function for the Audit Committee by establishing an internal audit review team which is independent
from the current accounting team
4. Improve compliance by expanding the legal team and strengthening its functions (1st quarter of 2019)
- Reorganize the legal team into an advisory department which reports directly to CEO
5. Strengthen the Intercompany Transaction Committee’s standards (1st quarter of 2019)
- Enhance transparency in transactions with specially-related parties
Further, the Company will exert its best efforts to prove the appropriateness of accounting through the administrative litigation and commit itself fully to the business to meet the expectations of investors and clients.
Thank you.
Dear Shareholders and Investors:
It is very fortunate that on December 10, 2018, the Korea Exchange decided to resume the stock trading of Samsung Biologics (the “Company”) in order to protect investors.
With the KOSPI listing in 2016, the Company changed its management practice from management centered on inside directors to management centered on independent directors, thereby improving its management transparency.
Also, since August 2016, the Company has further improved its management transparency by establishing and operating an audit committee whose chairman is an accounting professor.
The Company, as a global biotechnology company, plans to further strengthen its management transparency in order to better meet the market and social needs as follows:
1. Strengthen the internal control system for prevention and post-verification (2nd quarter of 2019)
- After reviewing current business process, build and operate an efficient and powerful internal control system based thereon
2. Enhance the practical auditing function by improving items that are insufficient than as directed
in the Audit Committee's Model Guidelines (1st quarter of 2019)
- Promote periodic inspection and strengthen the support system with an external professional agency
3. Specialize supervision function of the internal accounting management through the operation of
the Audit Committee (1st quarter of 2019)
- Strengthen the support function for the Audit Committee by establishing an internal audit review team which is independent
from the current accounting team
4. Improve compliance by expanding the legal team and strengthening its functions (1st quarter of 2019)
- Reorganize the legal team into an advisory department which reports directly to CEO
5. Strengthen the Intercompany Transaction Committee’s standards (1st quarter of 2019)
- Enhance transparency in transactions with specially-related parties
Further, the Company will exert its best efforts to prove the appropriateness of accounting through the administrative litigation and commit itself fully to the business to meet the expectations of investors and clients.
Thank you.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO